The Non-Inflammasome NLRs in Immunity and Host defense
免疫和宿主防御中的非炎性体 NLR
基本信息
- 批准号:9243972
- 负责人:
- 金额:$ 44.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-15 至 2021-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAutoimmune DiseasesAutoimmune ProcessAwardBacterial InfectionsBiochemicalCASP1 geneCellsCellular StressCommunicable DiseasesComplexDataDiseaseEmployee StrikesFRAP1 geneFamilyGenerationsGenesGenetic PolymorphismGrantHereditary DiseaseHost DefenseHumanIRAK1 geneImmuneImmune System DiseasesImmune responseImmune signalingImmunityImmunologic ReceptorsImmunologyImmunosuppressionIn VitroInfectionInflammasomeInflammationInflammatoryInfluenza A virusInterleukin-1 betaInterleukin-18LeadLinkMAP Kinase GeneMalignant NeoplasmsMediatingMissense MutationModelingMolecularMorbidity - disease rateMusMutationNational Institute of Allergy and Infectious DiseaseNatural ImmunityOutcomePathologyPathway interactionsPatientsPeptidoglycanPhysiologicalPlayPredispositionProto-Oncogene Proteins c-aktRecruitment ActivityRegulationRegulatory PathwayResearchRoleSignal PathwaySignal TransductionT-LymphocyteTestingTherapeuticToll-like receptorsUbiquitinVaccinesVirus DiseasesWorkadaptive immune responseadaptive immunityautoinflammatorybasecancer cellcytokinedesignexhaustionexperimental studyhuman diseaseimmunopathologyimmunoregulationimprovedin vivointerestmacrophagemembermortalitymulticatalytic endopeptidase complexnovelpathogenprematureprotein complexpublic health relevancereceptorresponsesensor
项目摘要
DESCRIPTION (provided by applicant): NOD-like receptors (NLRs) are a family of intracellular sensor molecules involved in the regulation of inflammatory signaling in response to infection and cellular stress. Recent studies have revealed pivotal roles for NLR-mediated inflammation in a spectrum of diverse human autoimmune and inflammatory disorders. The vast majority of NLRs to date have been defined as activators of inflammatory signaling in innate immune cells. For instance, the prototypical NLR members, NOD1 and NOD2, initiate proinflammatory NF-κB and MAPK signaling in response to their direct recognition of bacterial peptidoglycan fragments. Multiple NLRs have also been described to promote the activation and secretion of the proinflammatory cytokines IL-1β and IL-18 by coordinating the assembly of the inflammasome complex. In contrast, some NLRs, such as NLRP6, NLRP12, NLRC3 and NLRX1, negatively regulate inflammatory signaling. However, the cellular and molecular mechanisms that direct the suppression of inflammation by this new class of inhibitory NLRs are not known. Missense mutations in NLRP12 are associated with inflammatory diseases in humans, but the biochemical mechanisms and pathways underlying these pathologies remain unclear. Recent work from our lab demonstrates that NLRP12 functions as a key negative regulator of NF-κB signaling. Importantly, inflammation and immunopathology are not exclusively restricted to inflammatory and autoimmune diseases. The dysregulation of innate and adaptive immunity can also result in striking differences with regard to morbidity and mortality during infectious disease. In this regard, NLRP12's role in viral infection and generation of adaptive immune responses has not been investigated. Therefore, this project is highly significant, as it will lead to the identification of key immune mechanisms involved in host
defense and inflammatory control mechanisms dependent on NLRP12 that regulate inflammation. We will examine these mechanisms through the use of influenza A virus.
描述(由申请人提供):NOD样受体(NLR)是细胞内传感器分子家族,参与响应感染和细胞应激而调节炎症信号传导。最近的研究揭示了 NLR 介导的炎症在一系列不同的人类自身免疫和炎症性疾病中的关键作用。迄今为止,绝大多数 NLR 已被定义为先天免疫细胞中炎症信号传导的激活剂。例如,典型的 NLR 成员 NOD1 和 NOD2 响应其对细菌肽聚糖片段的直接识别,启动促炎 NF-κB 和 MAPK 信号传导。多个 NLR 也被描述为通过协调炎性体复合物的组装来促进促炎细胞因子 IL-1β 和 IL-18 的激活和分泌。相反,一些 NLR,例如 NLRP6、NLRP12、NLRC3 和 NLRX1,负向调节炎症信号传导。然而,这种新型抑制性 NLR 抑制炎症的细胞和分子机制尚不清楚。 NLRP12 的错义突变与人类炎症性疾病相关,但这些病理背后的生化机制和途径仍不清楚。我们实验室最近的工作表明,NLRP12 是 NF-κB 信号传导的关键负调节因子。重要的是,炎症和免疫病理学不仅仅局限于炎症和自身免疫性疾病。先天性和适应性免疫的失调也可能导致传染病期间发病率和死亡率的显着差异。在这方面,NLRP12 在病毒感染和适应性免疫反应产生中的作用尚未得到研究。因此,该项目非常重要,因为它将导致宿主关键免疫机制的鉴定。
防御和炎症控制机制依赖于调节炎症的 NLRP12。我们将通过使用甲型流感病毒来研究这些机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thirumala-Devi Kanneganti其他文献
Thirumala-Devi Kanneganti的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thirumala-Devi Kanneganti', 18)}}的其他基金
Regulation of lung inflammatory and antiviral responses during coronavirus infection
冠状病毒感染期间肺部炎症和抗病毒反应的调节
- 批准号:
10631757 - 财政年份:2021
- 资助金额:
$ 44.88万 - 项目类别:
Targeting innate immune pathways, and inflammatory cell death in cytokine-mediated diseases
针对细胞因子介导疾病中的先天免疫途径和炎症细胞死亡
- 批准号:
10622511 - 财政年份:2021
- 资助金额:
$ 44.88万 - 项目类别:
Targeting innate immune pathways, and inflammatory cell death in cytokine-mediated diseases
针对细胞因子介导疾病中的先天免疫途径和炎症细胞死亡
- 批准号:
10428652 - 财政年份:2021
- 资助金额:
$ 44.88万 - 项目类别:
Targeting innate immune pathways, and inflammatory cell death in cytokine-mediated diseases
针对细胞因子介导疾病中的先天免疫途径和炎症细胞死亡
- 批准号:
10311802 - 财政年份:2021
- 资助金额:
$ 44.88万 - 项目类别:
Innate immune sensors, inflammasomes, and inflammasome-mediated processes in cancer
癌症中的先天免疫传感器、炎症小体和炎症小体介导的过程
- 批准号:
10633206 - 财政年份:2020
- 资助金额:
$ 44.88万 - 项目类别:
Innate immune sensors, inflammasomes, and inflammasome-mediated processes in cancer
癌症中的先天免疫传感器、炎症小体和炎症小体介导的过程
- 批准号:
10220912 - 财政年份:2020
- 资助金额:
$ 44.88万 - 项目类别:
Innate immune sensors, inflammasomes, and inflammasome-mediated processes in cancer
癌症中的先天免疫传感器、炎症小体和炎症小体介导的过程
- 批准号:
10442693 - 财政年份:2020
- 资助金额:
$ 44.88万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:














{{item.name}}会员




